/REPL

REPL Stock - Replimune Group, Inc.

Q: What is the analyst price target for REPL?

Analyst price target information is not currently available for REPL.

Q: What is REPL's market cap?

Market capitalization information is not currently available for REPL.

Healthcare|Biotechnology|NASDAQ

$8.04-0.80%

$0.07 (-0.80%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+70.0%upside

Target: $13.67

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for REPL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.73

52W High$14.79

52W Low$2.68

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	$-4,575,000	$-4,139,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-261,627,000	$-234,773,000	$-177,080,000	$-121,484,000	$-82,762,000
Net Income	$-247,297,000	$-215,794,000	$-174,284,000	$-118,036,000	$-80,870,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-3.07	$-3.24	$-2.99	$-2.26	$-1.75

Company Overview

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Visit Website

Earnings History & Surprises

REPL

Beat Rate

39%

Last 18 quarters

Avg Surprise

-2.3%

EPS vs Estimate

Beats / Misses

7/10

1 met exactly

Latest EPS

$-0.90

Q4 2025

EPS Surprise History

Q1 24

+18.1%

$-0.77vs$-0.94

Q2 24

+4.7%

$-0.82vs$-0.86

Q3 24

+11.4%

$-0.78vs$-0.88

Q4 24

+9.3%

$-0.68vs$-0.75

Q1 25

-12.9%

$-0.79vs$-0.70

Q2 25

-9.3%

$-0.82vs$-0.75

Q3 25

-14.5%

$-0.95vs$-0.83

Q4 25

-3.4%

$-0.90vs$-0.87

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 20, 2026	—	—	—	—
Q1 2026	Feb 11, 2026	$-0.85	—	—	—
Q4 2025	Nov 6, 2025	$-0.87	$-0.90	-3.4%	✗ MISS
Q3 2025	Aug 7, 2025	$-0.83	$-0.95	-14.5%	✗ MISS
Q2 2025	May 22, 2025	$-0.75	$-0.82	-9.3%	✗ MISS
Q1 2025	Feb 12, 2025	$-0.70	$-0.79	-12.9%	✗ MISS
Q4 2024	Nov 12, 2024	$-0.75	$-0.68	+9.3%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.88	$-0.78	+11.4%	✓ BEAT
Q2 2024	May 16, 2024	$-0.86	$-0.82	+4.7%	✓ BEAT
Q1 2024	Feb 8, 2024	$-0.94	$-0.77	+18.1%	✓ BEAT
Q4 2023	Nov 7, 2023	$-0.80	$-0.90	-12.5%	✗ MISS
Q3 2023	Aug 3, 2023	$-0.85	$-0.75	+11.8%	✓ BEAT
Q2 2023	May 18, 2023	$-0.66	$-0.74	-12.1%	✗ MISS
Q1 2023	Feb 9, 2023	$-0.77	$-0.69	+10.4%	✓ BEAT
Q4 2022	Nov 3, 2022	$-0.78	$-0.79	-1.3%	✗ MISS
Q3 2022	Aug 4, 2022	$-0.63	$-0.78	-23.8%	✗ MISS
Q2 2022	May 19, 2022	$-0.60	$-0.60	0.0%	= MET
Q1 2022	Feb 3, 2022	$-0.58	$-0.57	+1.7%	✓ BEAT
Q4 2021	Nov 4, 2021	$-0.55	$-0.56	-1.8%	✗ MISS
Q3 2021	Aug 6, 2021	$-0.45	$-0.53	-17.8%	✗ MISS

Frequently Asked Questions about REPL

What is REPL's current stock price?

Replimune Group, Inc. (REPL) is currently trading at $8.04 per share. The stock has moved -0.80% today.

What is the analyst price target for REPL?

The average analyst price target for REPL is $13.67, based on 1 analyst.

What sector is Replimune Group, Inc. in?

Replimune Group, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is REPL's market cap?

Replimune Group, Inc. has a market capitalization of $0.63 billion, making it a small-cap company.

Does REPL pay dividends?

No, Replimune Group, Inc. does not currently pay a dividend to shareholders.